Skip to main content

Table 1 Patient demographics and baseline clinical characteristics

From: Transitioning subcutaneous immunoglobulin 20% therapies in patients with primary and secondary immunodeficiencies: Canadian real-world study

Parametera Cohort 1
(n = 23)
Cohort 2
(n = 75)
Cohort 3
(n = 27)
Total
(N = 125)
Age, years     
 Mean (SD) 65.6 (13.7) 61.8 (13.2) 60.1 (13.9) 62.1 (13.5)
 Median (range) 67 (32–82) 65 (19–83) 62 (28–79) 65 (19–83)
Sex     
 Female, n (%) 19 (82.6) 47 (62.7) 17 (63.0) 83 (66.4)
 Male, n (%) 4 (17.4) 28 (37.3) 10 (37.0) 42 (33.6)
Immunodeficiency diagnosisb     
 PID diagnosis, n (%) 10 (43.5) 32 (42.7) 19 (70.4) 61 (48.8)
  CVID 5 (50.0) 24 (75.0) 14 (73.7) 43 (70.5)
  Isolated IG subclass deficiency 0 1 (3.1) 2 (10.5) 3 (4.9)
  IgG2 deficiency 0 1 (3.1) 2 (10.5) 3 (4.9)
  Specific antibody deficiency with normo- or hypogammaglobulinemia 0 1 (3.1) 1 (5.3) 2 (3.3)
  Unclassified antibody deficiency 2 (20.0) 3 (9.4) 0 5 (8.2)
  Combined IgA/IgG subclass deficiency 1 (10.0) 0 0 1 (1.6)
  Other 2 (20.0) 6 (18.8) 2 (10.5) 10 (16.4)
SID associated with, n (%) 13 (56.5) 44 (58.7) 8 (29.6) 65 (52.0)
  Chronic lymphocytic leukemia 3 (23.1) 27 (61.4) 6 (75.0) 36 (55.4)
  Multiple myeloma 2 (15.4) 2 (4.5) 0 4 (6.2)
  Post-allogeneic HSCT 1 (7.7) 0 0 1 (1.5)
  Other 7 (53.8) 15 (34.1) 2 (25.0) 24 (36.9)
  1. an value for each parameter is presented based on available data and percentages are calculated as a proportion of those values
  2. bOne patient had a diagnosis of both PID and SID